| EG |
Report |
Operating EPS |
BEAT |
pred ~$15.20 vs. cons $14.59 |
MEDIUM |
| EG |
Report |
Combined ratio (group) |
BEAT |
pred ~90.5% vs. cons ~91.5% (lower=better) |
MEDIUM |
| EG |
Report |
Net investment income |
IN-LINE |
pred ~$550M vs. cons ~$545M |
LOW |
| EG |
Guide |
Share buyback pace |
BETTER |
guide ~$300M+/qtr vs. cons ~$250M/qtr (FY26) |
MEDIUM |
| EG |
Guide |
H2 capital release (AIG renewal-rights + Canada sale) |
BETTER |
guide ~$500M+ vs. cons ~$300M (H2 2026) |
LOW |
| EG |
Guide |
June/Florida cat rate change |
UNCHANGED |
guide ~-15% vs. broker ~-17% (6/1 2026 renewal) |
LOW |
| EG |
Guide |
FY26 Legacy combined ratio |
UNCHANGED |
guide >110% vs. cons ~110% (FY26) |
LOW |
| EG |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.0% |
— |
MEDIUM |
| EG |
Return |
5-day cumulative residual |
-4.0% (FADE) |
Even with a clean modest beat, the quality is low (seasonally light cat + volatile alt/NII), while the premium base is deliberately shrinking and consensus itself models earnings down YoY. Out-period math implies continued FY26 estimate drift lower, and the stock ran ~30% off lows and ~11% in July into the print at ~1.0x BV — a rich, 'priced-for-execution' bar. Absent a firm H2 capital-release number or a clear casualty all-clear, momentum fades as buy-the-news exhaustion and flat-to-lower revisions dominate; any Baltimore-bridge/summer reserve-study charge accelerates the fade. |
LOW |